Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

31. Juli 2019 06:00 ET | Quelle: Mesoblast Limited

Mesoblast Quarterly Cash Flow Report

MELBOURNE, Australia and NEW YORK, July 31, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today reported its operational highlights and its quarterly cash flows for the fourth...
25. Juli 2019 06:00 ET | Quelle: Mesoblast Limited

Circulation Research Special Article Highlights Potential Of Mesoblast Cell Therapy In Treatment Of Advanced Heart Failure

NEW YORK, July 25, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced that premier cardiovascular journal Circulation Research has published a Special Article...
24. Juni 2019 06:00 ET | Quelle: Mesoblast Limited

Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Designation From FDA for Prevention of Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices

NEW YORK and MELBOURNE, Australia, June 24, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, announced today that...
18. Juni 2019 06:00 ET | Quelle: Mesoblast Limited

High Economic Burden in Children With Steroid Refractory Acute Graft Versus Host Disease

Mesoblast Presents Health Economics and Outcomes Research Data at 24th European Hematology Association Congress MELBOURNE, Australia; and NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Mesoblast...
14. Juni 2019 13:44 ET | Quelle: Mesoblast Limited

UPDATE - Mesoblast to Host Virtual Symposium With Key Opinion Leader Highlighting Acute Graft Versus Host Disease

NEW YORK and MELBOURNE, Australia, June 14, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, today announced that...
14. Juni 2019 10:28 ET | Quelle: Mesoblast Limited

Mesoblast to Host Virtual Symposium With Key Opinion Leader Highlighting Acute Graft Versus Host Disease

NEW YORK and MELBOURNE, Australia, June 14, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, today announced that...
11. Juni 2019 06:00 ET | Quelle: Mesoblast Limited

Mesoblast and JCR Pharmaceuticals Expand Japan License Agreement to Use of Mesenchymal Stem Cells in Newborns With Insufficient Blood Flow to the Brain

NEW YORK and MELBOURNE, Australia, June 11, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced it has expanded its partnership with JCR Pharmaceuticals Co. Ltd. in...
30. Mai 2019 19:09 ET | Quelle: Mesoblast Limited

Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019

MELBOURNE, Australia and NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported its financial results and operational highlights for the nine months ended...
30. Mai 2019 06:00 ET | Quelle: Mesoblast Limited

Mesoblast Financial Results Webcast for Period Ended March 31, 2019

MELBOURNE, Australia and NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) will report financial results for the period ended March 31, 2019 in a webcast beginning...
29. Mai 2019 20:49 ET | Quelle: Mesoblast Limited

Mesoblast Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for remestemcel-L in the Treatment of Acute Graft Versus Host Disease

MELBOURNE, Australia and NEW YORK, May 29, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that it...

Vorherige Seite